IL-6 levels were significantly elevated in patients with advanced-stage CC compared to those with early-stage disease (156.7 (IQR: 130.4–227.6) versus 324.7 (IQR: 188.5–516.2) ng/mL) and in patients diagnosed with squamous cells carcinoma (SCC) compared to those without SCC (523.9 (IQR: 365.1–682.1) versus 203.6 (IQR: 131.3–334.3) ng/mL). Here, IL6 is linked to squamous cell carcinoma.